09-Oct-2019
Four members of DTU attended the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Barcelona to present accepted abstracts.
Shishi Xu, a visiting researcher from West China Hospital of Sichuan University, presented a risk prediction model for new-onset type 2 diabetes in an Asian population in a poster titled 'Predicting risk of new-onset type 2 diabetes (T2D) in Chinese people with coronary heart disease and impaired glucose tolerance'. She reported that major predictors of new-onset diabetes in this population include lower age, male sex, obesity, and drug treatment with corticosteroids, calcium channel blockers or thiazide diuretics. A risk calculator utilising these variables and measures of glycaemia could assist clinicians when considering primary T2D prevention measures.
In the same session Ruth Coleman presented an external validation of the UKPDS outcomes model version 2 (UKPDS OM2) on data from the EXSCEL trial in her poster titled 'Estimating cardiovascular risk in people with type 2 diabetes using the UKPDS outcomes model'. She reported that the three year model estimates for myocardial infarction (MI) and stroke were similar to those seen in the trial, but that the model overestimated cardiovascular (CV) death and all-cause mortality.
In a session chaired by Professor Rury Holman, Charlie Scott presented his poster titled 'Risk factors of heart failure in the ACE trial population' which included observational analyses looking at risk factors for incident hospitalization for heart failure (hHF) in a high risk Asian population. Older age, higher plasma creatinine values, prior MI, atrial fibrillation, heart failure and stroke were associated with higher risk of hHF and CV death.
Dr. Ernesto Maddaloni from the Sapienza University of Rome gave an oral presentation on the 'Risk of microvascular complications in patients with latent autoimmune diabetes (LADA)'. He showed that patients with LADA, compared to patients with type 2 diabetes, have a lower risk of developing microvascular complications in the first 9 years after diagnoses. However after 9 years the risk is higher in LADA patients than in people with type 2 diabetes.